Teva and Samsung Bioepis Partner on Up to Six Biosimilars
Teva Pharmaceutical Industries Ltd. (TEVA) has entered into a global agreement with Samsung Bioepis Co., Ltd. for the development, licensing, and commercialization of up to six biosimilar candidates. Two investigational biosimilar candidates are already identified: SB41 referencing Fasenra (benralizumab), used in asthma treatment, and SB44 targeting another undisclosed reference product. The partnership aims to expand Teva's portfolio in the growing biosimilars market while leveraging Samsung Bioepis' expertise. Biosimilars are biologic drugs that mimic existing branded medications at lower costs, offering significant cost savings for healthcare systems.
Tickers: $TEVA